ADAM12 and ADAM17 gene expression in laser-capture microdissected and non-microdissected breast tumors

Pathology and Oncology Research

Volumn 17, Issue 2, 2011, Pages 375-385

  Narita, Diana ^a   Seclaman, Edward ^a   Ilina, Razvan ^a   Cireap, Natalia ^a   Ursoniu, Sorin ^a   Anghel, Andrei ^a  

^a VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

ADAM12; ADAM17; Breast tumors; Gene expression; Laser capture microdissection

Indexed keywords

ADAM PROTEIN; ADAM12 PROTEIN; ADAM17 PROTEIN; UNCLASSIFIED DRUG;

ADAM12L GENE; ADAM12S GENE; ADAM17 GENE; ADULT; AGED; ARTICLE; BREAST CANCER; BREAST TUMOR; CARCINOGENESIS; CONTROLLED STUDY; FEMALE; GENE; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; GENETIC REGULATION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; LASER CAPTURE MICRODISSECTION; MAJOR CLINICAL STUDY; RNA SPLICING; TUMOR CELL; TUMOR GROWTH;

ADAM PROTEINS; ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; LASERS; MEMBRANE PROTEINS; MICRODISSECTION; MIDDLE AGED; NEOPLASM STAGING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 80051623969     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-010-9336-9     Document Type: Article

References (46)

1. Blobel CP (2005) ADAMS: key components in EGFR signalling and development. Nat Rev Cancer 6:32-43 (Pubitemid 40064897)
2. Arribas J, Bech-Serra JJ, Santiago-Josefat B (2006) ADAMs, cell migration and cancer. Cancer Metastasis Rev 25:57-68 (Pubitemid 43723982)
3. Iba K, Albrechtsen R, Gilpin B, Fröhlich C et al (2000) The cysteine-rich domain of human ADAM 12 supports cell adhesion through syndecans and triggers signaling events that lead to β1 integrin-dependent cell spreading. J Cell Biol 149:1143-1156
4. Ohtsu H, Dempsey PJ, Eguchi S (2006) ADAMs as mediators of EGF receptor transactivation by G-protein-coupled receptors. Am J Physiol Cell Physiol 291:C1-C10
5. Mochizuki A, Okada Y (2007) ADAMs in cancer cell proliferation and progression. Cancer Sci 98:621-628 (Pubitemid 46563436)
6. Murphy G (2008) The ADAMs: signalling scissors in the tumor microenvironment. Nature Reviews Cancer 8:929-941
7. Edwards DR, Handsley MM, Pennington CJ (2008) The ADAM metalloproteinases. Mol Aspects Med 29:258-289
8. Duffy MJ, McKiernan E, O'Donovan N, McGowan P (2009) Role of ADAMs in Cancer Formation and Progression. Clin Cancer Res 15:1140-1144
9. Jacobsen J, Wewer UM (2009) Targeting ADAM12 in human disease: head, body or tail? Curr Pharm Des 15:2300-2310
10. Kveiborg M, Albrechtsen R, Couchman JR, Wewer UM (2008) Cellular roles of ADAM12 in health and disease. Int J Biochem Cell Biol 40:1685-1702
11. Wewer UM, Mörgelin M, Holck P et al (2006) ADAM12 is a four-leafed clover. The excised prodomain remains bound to the mature enzyme. J Biol Chem 14:9418-9422 (Pubitemid 43864658)
12. Fröhlich C, Albrechtsen R, Dyrskjot L et al (2006) Molecular profiling of ADAM12 in human bladder cancer. Clin Cancer Res 12:7359-7368 (Pubitemid 46095409)
13. Kveiborg M, Fröhlich C, Albrechtsen R et al (2005) A role for ADAM 12 in breast tumor progression and stromal cell apoptosis. Cancer Res 65:4754-4760
14. Peduto L, Reuter VE, Schara-Fujisawa A et al (2006) ADAM12 is highly expressed in carcinoma-associated stroma and is required for mouse prostate tumor progression. Oncogene 25:5462-5466 (Pubitemid 44330288)
15. Sorensen HP, Vives RR, Manetopoulos C et al (2008) Heparan sulfate regulates ADAM12 through a molecular switch mechanism. J Biol Chem 46:31920-31932
16. O'Shea C, McKie N, Buggy Y et al (2003) Expression of ADAM-9 mRNA and protein in human breast cancer. Int J Cancer 105:754-761 (Pubitemid 36706097)
17. Lendeckel U, Kohl J, Arndt M et al (2005) Increased expression of ADAM family members in human breast cancer and breast cancer cell lines. J Cancer Res Clin Oncol 131:41-48
18. Kuefer R, Day KC, Kleer CG et al (2006) ADAM15 disintegrin is associated with aggressive prostate and breast cancer diseases. Neoplasia 8:319-329
19. Sjöblom T, Jones S, Wood L et al (2006) The consensus coding sequences of human breast and colorectal cancers. Science 314:268-274 (Pubitemid 44571966)
20. Borrell-Pages M, Rojo F, Albanell J, Baselga J, Arribas J (2003) TACE is required for the activation of the EGFR by TGF-alpha in tumors. EMBO J 22:1114-1124 (Pubitemid 36313595)
21. Zheng Y, Saftig P, Hartmann D, Blobel C (2004) Evaluation of the contribution of different ADAMs to tumor necrosis factor α (TNF α) shedding and of the function of the TNF α ectodomain in ensuring selective stimulated shedding by the TNF α convertase (TACE/ADAM17). J Biol Chem 41:42898-42906 (Pubitemid 39372180)
22. Kawaguchi N, Horiuchi K, Becherer JD, Toyama Y, Besmer P, Blobel CP (2007) Different ADAMs have distinct influences on Kit ligand processing: phorbol-ester-stimulated ectodomain shedding of Kitl1 by ADAM17 is reduced by ADAM19. J Cell Science 120:943-952 (Pubitemid 46638509)
23. Horiuchi K, Le Gall S, Schulte M, Yamaguchi T et al (2007) Substrate selectivity of epidermal growth factor-receptor ligand sheddases and their regulation by phorbol esters and calcium influx. Mol Biol Cell 18:176-188 (Pubitemid 46066719)
24. McGowan PM, McKiernan E, Bolster F et al (2008) ADAM-17 predicts adverse outcome in patients with breast cancer. Ann Oncol 19:1075-1081 (Pubitemid 351796332)
25. Zucker S, Cao J, Chen WT (2000) Critical appraisal of the use of matrix metalloproteinases inhibitors in cancer treatment. Oncogene 19:6642-6650 (Pubitemid 32197703)
26. Zhou BB, Petyon M, He B et al (2006) Targeting ADAM-mediated ligand cleavage toinhibit HER2 and EGFR pathways in non-small cell lung cancer. Cancer Cell 10:39-50 (Pubitemid 44018087)
27. Liu X, Fridman JS, Wang Q et al (2006) Selective inhibition of ADAM metalloproteases blocks HER-2 extracellular domain (ECD) cleavage and potentiates the anti-tumor effects of trastuzumab. Cancer Biol Ther 5:648-656 (Pubitemid 44024720)
28. Fridman JS, Caulder E, Hansbury M (2007) Selective inhibition of ADAM metalloproteases as a novel approach for modulating ErbB pathways in cancer. Clin Cancer Res 13:1892-1902 (Pubitemid 46952960)
29. Emmert-Buck MR, Bonner RF, Smith PD et al (1996) Lasercapture microdissection. Science 274:998-1001
30. Fend F, Raffeld M (2000) Laser capture microdissection in pathology. J Clin Pathol 53:666-672
31. Okuducu AF, Jansen V, Hahne JC et al (2003) Influence of histochemical stains on quantitative gene expression analysis after laser-assisted microdissection. Int J Mol Med 11:449-453
32. Espina V, Wulfkuhle JD, Calvert VS et al (2006) Laser-capture microdissection. Nature Protocols 2:586-602
33. De Kok JB, Roelofs RW, Giesendorf BA et al (2005) Normalization of gene expression measurements in tumor tissues: comparison of 13 endogenous control genes. Lab Invest 85:154-159 (Pubitemid 40128049)
34. -ΔΔCT method. Methods 25:402-408 (Pubitemid 34164012)
35. Michel C, Desdouets C, Sacre-Salem B et al (2003) Liver gene expression profiles of rats treated with clofibric acid. Comparison of whole liver and laser capture microdissected liver. Am J Pathol 6:2191-2199 (Pubitemid 37466464)
36. Erickson HS, Albert PS, Gillespie WJ et al (2007) Normalization strategies for quantitative RT-PCR in microdissected tissue. Lab Invest 87:951-962 (Pubitemid 47267819)
37. Shi Z, Xu W, Loechel F, Wewer UM, Murphy LJ (2000) ADAM12, a disintegrin and metalloprotease, interacts with insulin-like growth factor-binding protein-3. J Biol Chem 275:18574-18580 (Pubitemid 30414820)
38. Laigaard J, Sørensen T, Fröhlich C et al (2003) ADAM12: a novel first-trimester maternal serum marker for Down syndrome. Prenat Diagn 23:1086-1091 (Pubitemid 38084153)
39. Roy R, Wewer MU, Zurakowski D, Pories ES, Moses MA (2004) ADAM 12 cleaves extracellular matrix proteins and correlates with cancer status and stage. J Biol Chem 49:51323-51330 (Pubitemid 40017878)
40. Pories S, Zurakowski D, Roy R et al (2008) Urinary metalloproteinases: noninvasive biomarkers for breast cancer risk assessment. Cancer Epidemiol Biomarkers Prev 17:1034-1042
41. Le Pabic H, Bonnier D, Wewer UM et al (2003) ADAM12 in human liver cancers: TGF-β-regulated expression in stellate cells is associated with matrix remodeling. Hepatology 37:1056-1066 (Pubitemid 36538682)
42. Kodama T, Ikeda E, Okada A et al (2004) ADAM12 is selectively overexpressed in human glioblastomas and is associated with glioblastoma cell proliferation and shedding of heparin-binding epidermal growth factor. Am J Pathol 165:1743-1753 (Pubitemid 39435171)
43. Dyczynska E, Syta E, Sun D, Zolkiewska A (2008) Breast cancer-associated mutations in metalloprotease disintegrin ADAM12 interfere with the intracellular trafficking and processing of the protein. Int J Cancer 122:2634-2640 (Pubitemid 351590502)
44. Atfi A, Dumont E, Colland F et al (2007) The disintegrin and metalloproteinase ADAM12 contributes to TGF-β signaling through interaction with the type II receptor. J Cell Biol 178:201-208 (Pubitemid 47076457)
45. Bierie B, Moses HL (2006) Tumor microenvironment: TGFβ: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 6:506-520 (Pubitemid 43980540)
46. Niimi H, Pardali K, Vanlandewijck M, Heldin CH, Moustakas A (2007) Notch signaling is necessary for epithelial growth arrest by TGF-β. J Cell Biol 176:695-707 (Pubitemid 46333983)